<DOC>
	<DOCNO>NCT00307021</DOCNO>
	<brief_summary>GSK Biologicals develop number candidate malaria vaccine routine immunization infant child live malaria-endemic area . The candidate vaccine design offer protection malaria disease due parasite Plasmodium falciparum . Candidate vaccine contain RTS , S antigen would also provide protection infection hepatitis B virus ( HBV ) . This study evaluate two candidate vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Double-blind Study Safety Immunogenicity Two Candidate Malaria Vaccines Gabonese Children</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : A male female child 18 month 4 year age ( include 5th birthday ) time first vaccination . Written oral , sign thumbprinted witness informed consent obtain parent ( ) /guardian ( ) child . Subjects investigator believe parents/guardians comply requirement protocol ( e.g . return followup visit ) Exclusion criterion : Acute disease time enrolment . Serious acute chronic illness determine clinical physical examination laboratory screen test . Laboratory screen test haemoglobin , total white cell count , platelet , ALT creatinine range . Planned administration/administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) exception tetanus toxoid . Use investigational nonregistered drug vaccine within 30 day precede first dose study vaccine , plan use study period . Administration immunoglobulins , blood transfusion blood product within three month precede first dose study vaccine plan administration study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Previous participation malaria vaccine trial . Simultaneous participation clinical trial . Same sex twin . History allergic reaction ( significant IgEmediated event ) anaphylaxis previous immunization . History allergic disease reaction likely exacerbate component vaccine . Any finding investigator feel would increase risk adverse outcome participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Parasitic Diseases</keyword>
	<keyword>Malaria , Falciparum</keyword>
	<keyword>Malaria</keyword>
	<keyword>Coccidiosis</keyword>
</DOC>